These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34068119)

  • 41. Malaria-Cutaneous Leishmaniasis Co-infection: Influence on Disease Outcomes and Immune Response.
    Pinna RA; Silva-Dos-Santos D; Perce-da-Silva DS; Oliveira-Ferreira J; Villa-Verde DM; De Luca PM; Banic DM
    Front Microbiol; 2016; 7():982. PubMed ID: 27446022
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Therapeutic Effects of Curcumin-coated Gold Nanoparticle Against Leishmania Major Causative Agent of Zoonotic Cutaneous Leishmaniasis (ZCL): An In Vitro and In Vivo Study.
    Amini SM; Hadighi R; Najm M; Alipour M; Hasanpour H; Vosoogh M; Vosough A; Hajizadeh M; Badirzadeh A
    Curr Microbiol; 2023 Feb; 80(4):104. PubMed ID: 36781499
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Diversity of Leishmania Strains Isolated from Cutaneous Leishmaniasis Patients in Turkey and its Reflection to Clinics in Mice Model].
    Özbilgin A; Çulha G; Güray MZ; Zeyrek FY; Akyar I; Töz S; Östan Ural İ; Kurt Ö; Kocagöz T; Çavuş İ; Gündüz C
    Mikrobiyol Bul; 2020 Jul; 54(3):429-443. PubMed ID: 32755519
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vivo imaging of transgenic Leishmania parasites in a live host.
    Thalhofer CJ; Graff JW; Love-Homan L; Hickerson SM; Craft N; Beverley SM; Wilson ME
    J Vis Exp; 2010 Jul; (41):. PubMed ID: 20689512
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improvements in obtaining New World Leishmania sp from mucosal lesions: notes on isolating and stocking parasites.
    Dorta ML; Oliveira MA; Fleuri AK; Duarte FB; Pinto SA; Pereira LI; Ribeiro-Dias F
    Exp Parasitol; 2012 Oct; 132(2):300-3. PubMed ID: 22728105
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dendritic Cells and Leishmania Infection: Adding Layers of Complexity to a Complex Disease.
    Feijó D; Tibúrcio R; Ampuero M; Brodskyn C; Tavares N
    J Immunol Res; 2016; 2016():3967436. PubMed ID: 26904694
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Leishmania cytochrome b gene sequence polymorphisms in southern Iran: relationships with different cutaneous clinical manifestations.
    Mohammadpour I; Hatam GR; Handjani F; Bozorg-Ghalati F; PourKamal D; Motazedian MH
    BMC Infect Dis; 2019 Jan; 19(1):98. PubMed ID: 30696426
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A fine mapping of single nucleotide variants and haplotype analysis of
    Junior JDES; de Souza JL; da Silva LS; da Silva CC; do Nascimento TA; de Souza MLG; da Cunha AF; Batista JDS; Neto JPM; Guerra MVF; Ramasawmy R
    Front Immunol; 2023; 14():1232488. PubMed ID: 37908348
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Leishmania species: A narrative review on surface proteins with structural aspects involved in host-pathogen interaction.
    Kaushal RS; Naik N; Prajapati M; Rane S; Raulji H; Afu NF; Upadhyay TK; Saeed M
    Chem Biol Drug Des; 2023 Aug; 102(2):332-356. PubMed ID: 36872849
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Successful Isolation of Leishmania RNA Virus (LRV) from Leishmania major in a Cutaneous Leishmaniasis Focus in Central Iran: An Update on Cases.
    Moin-Vaziri V; Zare F; Seyyed Tabaei SJ; Saberi R; Hajjaran H
    Acta Parasitol; 2022 Sep; 67(3):1290-1298. PubMed ID: 35773567
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro evaluation of CRISPR PX-LmGP63 vector effect on pathogenicity of Leishmania major as a primary step to control leishmaniasis.
    Ebrahimi S; Kalantari M; Alipour H; Azizi K; Asgari Q; Bahreini MS
    Microb Pathog; 2021 Dec; 161(Pt A):105281. PubMed ID: 34752910
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lymphocytes influence Leishmania major pathogenesis in a strain-dependent manner.
    Musa MA; Nakamura R; Hena A; Varikuti S; Nakhasi HL; Goto Y; Satoskar AR; Hamano S
    PLoS Negl Trop Dis; 2019 Nov; 13(11):e0007865. PubMed ID: 31738761
    [TBL] [Abstract][Full Text] [Related]  

  • 53. IL-32γ promotes the healing of murine cutaneous lesions caused by Leishmania braziliensis infection in contrast to Leishmania amazonensis.
    Gomes RS; Silva MVT; Dos Santos JC; de Lima Silva LL; Batista AC; Machado JR; Teixeira MM; Dorta ML; de Oliveira MAP; Dinarello CA; Joosten LAB; Ribeiro-Dias F
    Parasit Vectors; 2017 Jul; 10(1):336. PubMed ID: 28709468
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intradermal inoculations of low doses of Leishmania major and Leishmania amazonensis metacyclic promastigotes induce different immunoparasitic processes and status of protection in BALB/c mice.
    Courret N; Lang T; Milon G; Antoine JC
    Int J Parasitol; 2003 Oct; 33(12):1373-83. PubMed ID: 14527520
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Healed Lesions of Human Cutaneous Leishmaniasis Caused By
    Sghaier RM; Benhnini F; Guerfali FZ; Attia H; Bali A; Zaatour A; Mkannez G; Gharbi A; Belhaj-Hamida N; Dridi H; Ben-Salah A; Dellagi K; Laouini D
    Front Cell Infect Microbiol; 2022; 12():839216. PubMed ID: 35967864
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Changes in the microbiological diagnosis and epidemiology of cutaneous leishmaniasis in real-time PCR era: A six-year experience in a referral center in Barcelona.
    Silgado A; Armas M; Sánchez-Montalvá A; Goterris L; Ubals M; Temprana-Salvador J; Aparicio G; Chicharro C; Serre-Delcor N; Ferrer B; Molina I; García-Patos V; Pumarola T; Sulleiro E
    PLoS Negl Trop Dis; 2021 Nov; 15(11):e0009884. PubMed ID: 34758023
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Naloxone Effects Against Cutaneous Leishmaniasis Caused by
    Azizi H; Mahdavinik E; Hataminejad M; Khamesipour A; Montazeri S
    Infect Disord Drug Targets; 2023; 23(6):e020623217598. PubMed ID: 37278044
    [TBL] [Abstract][Full Text] [Related]  

  • 58. M1 homeopathic complex trigger effective responses against Leishmania (L) amazonensis in vivo and in vitro.
    Nascimento KF; de Santana FR; da Costa CRV; Kaplum V; Volpato H; Nakamura CV; Bonamin LV; de Freitas Buchi D
    Cytokine; 2017 Nov; 99():80-90. PubMed ID: 28738234
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An α-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major.
    Iniguez E; Schocker NS; Subramaniam K; Portillo S; Montoya AL; Al-Salem WS; Torres CL; Rodriguez F; Moreira OC; Acosta-Serrano A; Michael K; Almeida IC; Maldonado RA
    PLoS Negl Trop Dis; 2017 Oct; 11(10):e0006039. PubMed ID: 29069089
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of the A2 gene locus in Leishmania donovani and Leishmania major and its control over cutaneous infection.
    Zhang WW; Mendez S; Ghosh A; Myler P; Ivens A; Clos J; Sacks DL; Matlashewski G
    J Biol Chem; 2003 Sep; 278(37):35508-15. PubMed ID: 12829719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.